Skip to main content

Full text of "USPTO Patents Application 09848616"

See other formats


Please type a sign (+) insidjgHj^box 



ffl 



PTO/SB/05 (03-01) 
ted for use through 1 0/3 1/2002. OMB 065 1 -0032 
Patent and Ttz^WM Office: U.S. DEPARTMENT OF COMMERCE 
^UnderthePapenvork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 



raSBMfOf 



UTILITY 
PATENT APPLICATION 
TRANSMITTAL 

(Only for new nonprovisional applications under 3 7 CFR § 1.53(b)) 



Attorney Docket No. 



First Inventor 



Title 



1 700.01 80002/JAG/GER 



Peter Sebbel 



Molecular Antigen Array 



Express Mail Label No. 



APPLICATION ELEMENTS 

See MPEP chapter 600 concerning utility patent application contents. 



ADDRESS TO: 



Assistant Commissioner for Patents 
Box Patent Application 
Washington, DC 20231 



1- □ 

2. ^ 

3. [X] 



Fee Transmittal Form (e.g., PTO/SB/17) 
(Submit an original, and a duplicate for fee processing) 



7. □ CD-ROM or CD-R in duplicate, large table or Computer Program 

(Appendix) 

8. Nucleotide and/or Amino Acid Sequence Submission 



Applicant claims small entity status. 
See 37 CFR 1.27. 

Specification [Total Pages 

(preferred arrangement set forth below) 

- Descriptive title of the Invention 

- Cross Reference to Related Applications 

- Statement Regarding Fed sponsored R&D 

- Reference to sequence listing, a table, 
or a computer program listing appendix 

- Background of the Invention 

- Brief Summary of the Invention 

- Brief Description of the Drawings (if filed) 

- Detailed Description 

- Claim(s) 

- Abstract of the Disclosure 



161 



(if applicable, all necessary) 

a. ^ Computer Readable Form (CRF) 

b. Specification Sequence Listing on: 

i. □ CD-ROM or CD-R (2 copies); or 

ii. |3 paper 

c. £3 Statements verifying identity of above copies 



O 
I- 

" J <x> ; 

<M^ i 

vo<y\ ■ 

COQ • 

U s 



=© 
■si* 



-o 



4. ^ 



Drawing(s) (35 U.S.C. 113) [Total Sheets 27 1 

5. Oath or Declaration [Total Pages J 

a. □ Newly executed (original or copy) 

b. □ Copy from a prior application (37 CFR 1.63(d)) 

(for continuation/divisional with Box 18 completed) 

i. □ DELETION OF INVENTORY 

Signed statement attached deleting inventor(s) 
named in the prior application, see 37 CFR §§ 
1.63(d)(2) and 1.33(b). 

6. Application Data Sheet. See 37 CFR 1.76. 



ACCOMPANYING APPLICATION PARTS 



9. Q Assignment Papers (cover sheet & document(s)) 

10. □ 37 CFR 3.73(b) Statement □ Power of Attorney 

(when there is an assignee) 

11. n English Translation Document (if applicable) 

12. Information Disclosure I I Copies of IDS 
Statement (IDS)/PTO- 1449 Citations 

13. |3 Preliminary Amendment 

14. |3 Return Receipt Postcard (MPEP 503) 

(Should be specifically itemized} 

15. □ Certified Copy of Priority Document(s) 

(if foreign priority is claimed) 

16. n Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach 

form PTO/SB/35 or its equivalent. 

17 EEI Other: Authorization under 37 C.F.R. § 1.136(a)(3) 

Priority Claim Under 35 U.S.C. § 1 19(e) and 37 C.RR . 
§ 1 -78(a)(4) 

£3 Other: The name of the assignee is: Cvtos Biotechnology AG 



18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, 
or in an Application Data Sheet under 3 7 CFR 1. 76: 



D Continuation ^ Divisional CD Continuation-in-Part (CIP) 

Prior application information: Examiner 



of prior application No: 
Group/Art Unit: 



For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is 
considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporatio n can on ly 
reHe^upotjwhei^yjort^ 



19. CORRESPONDENCE ADDRESS 




Burden Hour Statement: this form is estimated ttVtake 0.2 hours toj complete. Time will vary depending upon the needs of the individual case. Any comments on the amount 
of time you are required to complete this reqnjibould be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 2023 1 . DO NOT SEND 
FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231 . 
SKGF Rev 3/29/01 mac 01 8-2 .NON-PRO V.CVR.WPD 



jc860 U.S. PTO 



Sterne, Kesslee, Goldstein & Fox f.l.l.c. 

ATTORNEYS AT LAW 
IIOO NEW YORK AVENUE, N.W. • WASHINGTON, D.C. 20005-3934 



Phone: (202> 371-26OO • Facsimile: 1202) 371-2540 • www.skgf.com 



Robert Greene Sterne 
Edward J. Kessler 
Jorge A. Goldstein 
Samuel L. Fox*** 
David K.S. Cornwell 
Robert w. Esmond 
Tracy-Gene G. Durkin 

MlCHELE A. C I M B ALA 

Michael B. Ray 
Robert E. Sokohl 
Eric k. Steffe 
Michael O. Lee 
Steven R. ludwig 



John m. Covert 
Linda E. Alcorn 
Robert C Millonig 
Michael V. Messinger 
Judith U. Kim 
Timothy J. Shea, Jr. 
Donald R. McPhail 
Patrick E. Garrett 
Jeffrey T. Helvey* 
Heidi L. Kraus 
Jeffrey R. Kurin 
Raymond Millien 
Patrick D. O'Brien 



Lawrence B. Bugaisky 
Crystal D. Sayles 
Edward W. Yee 
Albert L. Ferro* 
Donald R. Banowit 
Peter A. Jackman 
Molly A. McCall 
Teresa U. Medler 
Jeffrey S. Weaver 
Kristin K. Vidovich 
Kendrick P. Patterson 
Donald J. Featherstone 
Grant E. Reed 



Vincent L. Capuano 
John A. Harroun" 
Albert J. Fasulo tl* 
Eldora Ellison Floyd' 
w. Russell Swindell 
Thomas C Fiala 
Brian J. Del Buono* 
Virgil L. Beaston* 
Ryan J. Stamper* 
Karen R. Markowicz** 
Suzanne E. Ziska"* 
Andrea J. Kamage** 
Nancy J. Leith** 



May 4, 2001 



Elizabeth J. Haanes" 
Mark P. Terry** 
Joseph M. Conrad, lit* 
Douglas m. Wilson** 
Reginald D. Lucas" 
Ann E. Summerfield** 
Cynthia M. Bouchez** 
Helene C. Carlson** 
Bruce E. Chalker** 
Dustin T. Johnson" 
Matthew J. Dowd" 



•Limited To Matters 
and Proceedings Before 
Federal Courts & Agencies 

"Registered Patent agent 
•"Senior Counsel 

Writer 's Direct Number: 

(202)789-5507 



Commissioner for Patents Box Patent Application 

Washington, D.C. 20231 g 

Re: U.S. Non-Provisional Patent Application under 37 C.F.R. § 1.53(b) w^g 



Appl. No. To Be Assigned; Filed: May 4, 2001 
For: Molecular Antigen Array S^Tj^lin 

00 " * *^*^— o 

Inventors: Sebbel et al .u ^ 

Our Ref: 1 700.0 1 80002/JAG/GER 



Sir: 



The following documents are forwarded herewith for appropriate action by the U.S. 
Patent and Trademark Office: 

1 . USPTO Utility Patent Application Transmittal Form (PTO/SB/05); 

2. U.S. Utility Patent Application entitled: 



Molecular Antigen Array 

and naming as inventors: 

Peter Sebbel, 
Nicolas Dunant, 
Martin Bachmann, 
Alain Tissot, and 
Franziska Lechner; 



Fox p.l.l.c. 



Sterne, Kesslbb, Goldst 



Commissioner for Patents 
May 4, 2 001 
Page 2 



the application consisting of: 

a. A specification containing: 

i. 142 pages of description prior to the claims; 

ii. 18 pages of claims (125 claims); 

iii. a one ( 1 ) page abstract; 

b. TL sheets of drawings: (Figures 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 
13, 14A, 14B, 15A, 15B, 16A, 16B, 17, 18A, 18B, 18C, 18D, 19A, 
19B,and 20); 

c. 100 pages of a paper copy of the sequence listing; 

d. A computer readable copy of the sequence listing. In accordance 
with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing 
and the computer readable copy of the sequence listing submitted 
herewith in the above application are the same; 

e. an Application Data Sheet (37 C.F.R. § 1 .76); 

3. Preliminary Amendment; 

4. Priority Claim Under 35 U.S.C. § 1 19(e) and 37 C.F.R. § 1 .78(a)(4); 

5 . Authorization to Treat a Reply As Incorporating An Extension of Time 
Under 37 C.F.R. § 1.136(a)(3) (in duplicate); and 

6. Two (2) return postcards. 

The name of the assignee is Cytos Biotechnology AG. 
Send correspondence to Customer Number 261 1 1 . 

It is respectfully requested that, of the two attached postcards, one be stamped with the 
filing date of these documents and returned to our courier, and the other, prepaid postcard, be 
stamped with the filing date and unofficial application number and returned as soon as possible. 



Sterne, Kesslbe, GOLDST^ye Fox P.L.L.C 

Commissioner for Patents 
May 4, 2001 
Page 3 

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration 
and without filing fee. 

Respectfully submitted, 

Sterne, Kessler, Goldstein & Fox p.l.l.c. 



GrantfE. Reed 
Attomeyjftr Applicants 
RegiWtion No. 41,264 




Enclosures 

0 1 8-2.NON-PROV.TRANS.WPD 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 



In re application of: 



Confirmation No. 



Sebbel et al 



Art Unit: To Be Assigned 
Examiner: To Be Assigned 
Atty. Docket: 1 700.01 80002/JAG/GER 



Appl. No. To Be Assigned 

Filed: May 4,2001 

For: Molecular Antigen Array 



Authorization To Treat A Reply As Incorporating An Extension Of 
Time Under 37 C.F.R. § 1.136(a)(3) 

Commissioner for Patents 
Washington, D.C. 20231 



The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or 
future reply that requires a petition for an extension of time under this paragraph for its timely 
submission, as incorporating a petition for extension of time for the appropriate length of 
time. The U.S. Patent and Trademark Office is hereby authorized to charge all required 
extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise 
provided for in such reply. A duplicate copy of this authorization is enclosed. 



Sir: 



Respectfully submitted, 




Sterne, Kessler, Goldstein & Fox p.l.l.c. 



Date: 



1 100 New York Avenue, N.W. 
Suite 600 

Washington, D.C. 20005-3934 
(202)371-2600 



0 1 8-2.NON-PROV.AUTH.WPD 




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 



Appl. No.: To Be Assigned 
Filed: May 4, 2001 



In re application of: 



Sebbel et al 



Confirmation No. 



Examiner: To Be Assigned ^ 
Atty. Docket: 1 700.0 180002/JAG/GER 



Art Unit: To Be Assigned 




For: Molecular Antigen Array 

Priority Claim Under 35 U.S.C. § 119(e) And 37 C.F.R. § 1.78(a)(4) 

Commissioner for Patents 
Washington, D.C. 20231 

Sir: 

In accordance with 35 U.S.C. § 1 19(e) and 37 C.F.R. § 1.78(a)(4), the captioned 
non-provisional application claims priority benefit of U.S. provisional application no. 
60/202,341, filed May 5, 2000. 



Respectfully submitted, 



Sterne, Kessler, Goldstein & Fox p.l.l.c. 





Grant H. Rera / 
Attorng^for Applicants 
Registration No. 41,264 



1 1 00 New York Avenue, N. W. 
Suite 600 

Washington, D.C. 20005-3934 
(202)371-2600 



priority claim